Avanir Pharmaceuticals
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Avanir Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
Avanir Pharmaceuticals: 15 sponsored US clinical trials, none currently recruiting.
Avanir Pharmaceuticals sponsors 15 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 14 completed. 8 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depressive Disorder, Treatment-Resistant, with 1 trials.
Top-decile sponsor footprint
Avanir Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
14 of 15 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
15 total, page 1 of 1
Study to Assess the Bioavailability, Pharmacokinetics, Safety, and Tolerability of AVP-923 in Healthy Adult Participants
NCT03381664
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia
NCT02477670
Effectiveness, Safety, and Health-Related Outcomes of NUEDEXTA® in Nursing Home Patients With Pseudobulbar Affect (PBA)
NCT02496039
Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
NCT02153502
Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients
NCT01767129
Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)
NCT01799941
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease
NCT01584440
Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura
NCT01667679
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
NCT01324232
PRISM Registry: Pseudobulbar Affect Registry Series
NCT01366027
Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS
NCT00573443
Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy
NCT00113620
Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
NCT00056524
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
NCT00050232
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
NCT00021697
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 5 |
| Phase 3 | 6 |
| Phase 4 | 2 |
Therapeutic Areas
How the Avanir Pharmaceuticals archive is shaped
15 indexed studies, none listed as recruiting (0% open); 14 completed (93%).
Phase mix: 8 late (III/IV) vs 6 early (I/II) (balanced across stages).
Top condition: Depressive Disorder, Treatment-Resistant (1 trial), 4 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Avanir Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 15 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Avanir Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 archived trials
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Avanir Pharmaceuticals page
15 registered trials is a research-attention snapshot, not an endorsement of Avanir Pharmaceuticals or any single study.
- None of Avanir Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Depressive Disorder, Treatment-Resistant is the condition Avanir Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depressive Disorder, Treatment-Resistant trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Avanir Pharmaceuticals pipeline card: 15 registered trials from official public datasets.Report a data error.